1. Home
  2. LIXT vs ONCO Comparison

LIXT vs ONCO Comparison

Compare LIXT & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • ONCO
  • Stock Information
  • Founded
  • LIXT 2005
  • ONCO 2018
  • Country
  • LIXT United States
  • ONCO United States
  • Employees
  • LIXT N/A
  • ONCO N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • ONCO Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIXT Health Care
  • ONCO Health Care
  • Exchange
  • LIXT Nasdaq
  • ONCO Nasdaq
  • Market Cap
  • LIXT 4.1M
  • ONCO 4.6M
  • IPO Year
  • LIXT N/A
  • ONCO 2022
  • Fundamental
  • Price
  • LIXT $2.33
  • ONCO $0.53
  • Analyst Decision
  • LIXT
  • ONCO
  • Analyst Count
  • LIXT 0
  • ONCO 0
  • Target Price
  • LIXT N/A
  • ONCO N/A
  • AVG Volume (30 Days)
  • LIXT 18.9K
  • ONCO 17.2M
  • Earning Date
  • LIXT 11-12-2024
  • ONCO 12-10-2024
  • Dividend Yield
  • LIXT N/A
  • ONCO N/A
  • EPS Growth
  • LIXT N/A
  • ONCO N/A
  • EPS
  • LIXT N/A
  • ONCO N/A
  • Revenue
  • LIXT N/A
  • ONCO $1,870,605.00
  • Revenue This Year
  • LIXT N/A
  • ONCO N/A
  • Revenue Next Year
  • LIXT N/A
  • ONCO N/A
  • P/E Ratio
  • LIXT N/A
  • ONCO N/A
  • Revenue Growth
  • LIXT N/A
  • ONCO N/A
  • 52 Week Low
  • LIXT $1.31
  • ONCO $0.32
  • 52 Week High
  • LIXT $4.40
  • ONCO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 54.46
  • ONCO 41.58
  • Support Level
  • LIXT $2.25
  • ONCO $0.46
  • Resistance Level
  • LIXT $2.68
  • ONCO $0.76
  • Average True Range (ATR)
  • LIXT 0.23
  • ONCO 0.23
  • MACD
  • LIXT 0.01
  • ONCO 0.05
  • Stochastic Oscillator
  • LIXT 53.90
  • ONCO 9.97

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: